Kamada (KMDA) Capital Expenditures (2013 - 2026)
Kamada (KMDA) posted quarterly Capital Expenditures of -$973000.0 for Q1 2026, up 33.72% year-on-year from -$727643.4 in Q1 2025, and down 138.57% on a QoQ basis from $2.5 million in Q4 2025.
Kamada (KMDA) Capital Expenditures (2013 - 2026) Analysis & Trends
Kamada (KMDA) has reported Capital Expenditures for 14 consecutive years, with -$973000.0 the latest figure, recorded in Q1 2026.
- Quarterly Capital Expenditures rose 33.72% year-over-year to -$973000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$4.1 million (up 12.78% YoY) and the FY2025 annual result came in at -$9.8 million, down 603.63% from the prior year.
- Capital Expenditures eased to -$973000.0 in Q1 2026 per KMDA's latest filing, from $2.5 million in the prior quarter.
- Over the last five years, Capital Expenditures for KMDA reached as high as $2.5 million in Q4 2025 and fell as low as -$3.6 million in Q3 2025.
- A 5-year average of -$836043.1 and a median of -$977000.0 in 2022 frame the typical range for Capital Expenditures.
- The largest YoY upside for Capital Expenditures was 202.63% in 2024 against a maximum downside of 240007.43% in 2024.
- Year by year, Capital Expenditures stood at -$977000.0 in 2022, then jumped by 166.12% to $646000.0 in 2023, then surged by 202.63% to $2.0 million in 2024, then grew by 29.05% to $2.5 million in 2025, then slumped by 138.57% to -$973000.0 in 2026.
- According to Business Quant data, Capital Expenditures over the past three periods registered -$973000.0, $2.5 million, and -$3.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 168.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 110.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 1.95 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 99.60 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 39.90 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 1.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 51.00 Mn |
| 10 | Kamada | 401.22 Mn | 328.07 Mn | 19.12 Mn | -973,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -973,000.00 |
| Mar 31, 2026 | -973,000.00 |
| Dec 31, 2025 | 2.52 Mn |
| Dec 31, 2025 | 2.52 Mn |
| Sep 30, 2025 | -3.59 Mn |
| Sep 30, 2025 | -3.59 Mn |
| Jun 30, 2025 | -2.01 Mn |
| Jun 30, 2025 | -2.01 Mn |
| Mar 31, 2025 | -1.47 Mn |
| Mar 31, 2025 | -1.47 Mn |
| Dec 31, 2024 | 1.96 Mn |
| Dec 31, 2024 | 1.96 Mn |
| Sep 30, 2024 | -2.12 Mn |
| Sep 30, 2024 | -2.12 Mn |
| Jun 30, 2024 | -3.01 Mn |
| Jun 30, 2024 | -3.01 Mn |
| Mar 31, 2024 | -2.68 Mn |
| Mar 31, 2024 | -2.68 Mn |
| Dec 31, 2023 | 646,000.00 |
| Dec 31, 2023 | 646,000.00 |